WALTHAM, Mass., April 22, 2022 – Conjugate Group, a flexible drug development service provider to the biopharma industry, has been engaged as the preferred Medical Writing provider to a pioneering gene and cell therapy client headquartered in Cambridge, MA. With critical submissions deadlines on the horizon, The Conjugate Group has been tasked with producing a range of regulatory documents including Development Safety Update Reports (DSUR), Investigator Brochure (IB) Updates, and several Protocol Amendments. In addition, we have been asked to assist in the development of new document templates for use in future submissions.

About The Conjugate Group
Founded in 2017, Conjugate Group provides flexible resources to clients in the biopharmaceutical industry, with a focus on the clinical development lifecycle. A leader in Consulting and Contract Services, we offer individual resources, full-function outsourcing, and milestone focused tactical teams to help our clients operate effectively and efficiently.  We have helped numerous companies move products into and through the Clinic, from initial IND through registration and commercial launch.